Shares of Amarin are up 42% year-to-date as evidence of Vascepa's sales execution and potential "continues mounting every week," Jefferies analyst Michael Yee tells investors in a research note. After meeting with management, the analyst says the company continues to be bullish on accelerating market penetration and sales over the coming quarters. Further, management noted the window for the FDA to confirm any advisory panel is narrowing, given the priority review and the action date of September 28. With no panel, shares of Amarin move higher for a "straighter shot towards clean approval," Yee contends. Regarding patent litigation, a court date is set for January 2020, the analyst adds. If any settlement comes, the stock would move "quickly higher" towards $25-plus, according to Yee. He keeps a Buy rating on Amarin with a $30 price target. Amarin closed yesterday up 2 to $19.42.